The technetium-99m market size has grown strongly in recent years. It will grow from $4.75 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to limited availability of radiopharmaceuticals, rising prevalence of cardiovascular diseases, growth in nuclear medicine infrastructure, government healthcare initiatives, technological advancements in imaging modalities.
The technetium-99m market size is expected to see steady growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, expansion of hospital and imaging center networks, development of novel Tc-99m radiopharmaceuticals, integration of ai in nuclear imaging, rising awareness for early disease detection. Major trends in the forecast period include increased adoption of spect imaging, growth in cardiac and oncology diagnostics, short half-life radiopharmaceutical demand, expansion of centralized radiopharmacy services, regulatory compliance and safety enhancements.
The growing demand for diagnostic imaging procedures is expected to drive the growth of the technetium-99m market moving forward. Diagnostic imaging procedures involve medical techniques that create visual representations of the body’s interior, assisting doctors in diagnosing and sometimes guiding treatment for various conditions. This rising demand is largely due to the increasing prevalence of chronic diseases that require early and accurate diagnosis. Technetium-99m supports diagnostic imaging by enabling doctors to visualize organ and tissue functions with high precision, using its radioactive properties to produce detailed images during nuclear medicine scans. For example, according to NHS England, a UK government department, 45 million imaging tests were performed in England in the year ending March 2023, reflecting a 2.2% increase compared to the 44 million tests conducted the previous year. Thus, the rising demand for diagnostic imaging is fueling the technetium-99m market’s growth.
Companies in the technetium-99m market are focusing on developing innovative solutions such as advanced radiopharmaceutical imaging agents to improve the accuracy and accessibility of diagnostic imaging for complex medical conditions. These agents are special compounds labeled with radioactive materials that help doctors visualize internal body structures using imaging techniques. For instance, in June 2024, Serac Healthcare Limited, a UK-based clinical radiopharmaceutical company, received Fast Track Designation from the US FDA for 99mTc-maraciclatide, an innovative SPECT-CT imaging agent designed to visualize and diagnose superficial peritoneal endometriosis in women aged 16 and older. This agent is a technetium-99m-labeled targeted peptide that binds to integrins overexpressed in endometriosis lesions, allowing clear visualization of disease sites during SPECT-CT scans. It offers a non-invasive diagnostic alternative to laparoscopic procedures, providing a safer and more accessible diagnostic option for women suspected of having endometriosis. Utilizing the favorable imaging characteristics of technetium-99m, including its ideal half-life and gamma emission energy, this agent delivers high-quality diagnostic images while minimizing radiation exposure. This innovation is expected to improve diagnostic accuracy and support better treatment decisions in endometriosis management, while broadening the clinical use of technetium-99m-based imaging in women’s health.
In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed sum. Through this acquisition, Telix aims to strengthen its control over the supply chain for key medical isotopes such as technetium-99m by integrating ARTMS’s cyclotron-based radioisotope production technology. This move is intended to support large-scale, cost-effective, and reliable production of diagnostic and therapeutic isotopes within Telix’s radiopharmaceutical portfolio. ARTMS Inc. is a Canada-based company specializing in advanced cyclotron technologies for producing medical radioisotopes including technetium-99m.
Major companies operating in the technetium-99m market are Cardinal Health Inc, GE Healthcare Technologies Inc, BWX Technologies Inc, Bracco Imaging S p A, Lantheus Holdings Inc, China Isotope And Radiation Corporation, Jubilant Pharma Limited, Curium Pharma LLC, Eckert And Ziegler Strahlen, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, SHINE Technologies LLC, Medi Radiopharma Kft, SDS Lifesciences Pvt Ltd, ANSTO Nuclear Medicine, IRE ELiT, Sam Young Unitech Co Ltd, RadioMedix Inc, Institute Of Isotopes Co Ltd, Monrol Nuclear Products.
North America was the largest region in the technetium-99m market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the technetium-99m market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the technetium-99m market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the technetium-99m market by increasing the cost of imported radiopharmaceuticals, generators, and diagnostic kits, thereby impacting overall pricing and supply chain efficiency. The hospital-based generators and centralized radiopharmacy segments, particularly in regions like North America and Europe that rely on imports, are most affected. While tariffs may cause short-term cost increases, they also encourage local production of generators and radiopharmaceuticals, potentially leading to innovation and self-reliance in the nuclear medicine supply chain.
The technetium-99m market research report is one of a series of new reports that provides technetium-99m market statistics, including technetium-99m industry global market size, regional shares, competitors with a technetium-99m market share, detailed technetium-99m market segments, market trends and opportunities, and any further data you may need to thrive in the technetium-99m industry. This technetium-99m market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Technetium-99m (Tc-99m) is a radioactive isotope of technetium commonly used in nuclear medicine for diagnostic imaging. It emits gamma rays that can be detected by a gamma camera, enabling visualization of internal organs and structures. With a short half-life of approximately 6 hours, Tc-99m limits patient radiation exposure while delivering clear imaging results.
The primary products related to technetium-99m include radiopharmaceuticals, diagnostic kits, and generators. Radiopharmaceuticals are radioactive compounds used in medical imaging and therapy for diagnosis or treatment. These are available in various formulations such as liquid, solid, and freeze-dried forms. Applications span single photon emission computed tomography (SPECT), positron emission tomography (PET), oncology, cardiology, neurology, and more. The key end users include hospitals, diagnostic imaging centers, research laboratories, specialized clinics, and other healthcare facilities.
The technetium-99m market includes revenues earned by entities by providing services such as diagnostic imaging, functional imaging, medical diagnostic imaging, cardiac imaging, and cancer detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The technetium-99m market also includes sales of technetium-99m sestamibi, mercaptoacetyltriglycine, hexamethylpropyleneamine oxime, technetium-99m pertechnetate, and diethylenetriamine pentaacetic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The technetium-99m market size is expected to see steady growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, expansion of hospital and imaging center networks, development of novel Tc-99m radiopharmaceuticals, integration of ai in nuclear imaging, rising awareness for early disease detection. Major trends in the forecast period include increased adoption of spect imaging, growth in cardiac and oncology diagnostics, short half-life radiopharmaceutical demand, expansion of centralized radiopharmacy services, regulatory compliance and safety enhancements.
The growing demand for diagnostic imaging procedures is expected to drive the growth of the technetium-99m market moving forward. Diagnostic imaging procedures involve medical techniques that create visual representations of the body’s interior, assisting doctors in diagnosing and sometimes guiding treatment for various conditions. This rising demand is largely due to the increasing prevalence of chronic diseases that require early and accurate diagnosis. Technetium-99m supports diagnostic imaging by enabling doctors to visualize organ and tissue functions with high precision, using its radioactive properties to produce detailed images during nuclear medicine scans. For example, according to NHS England, a UK government department, 45 million imaging tests were performed in England in the year ending March 2023, reflecting a 2.2% increase compared to the 44 million tests conducted the previous year. Thus, the rising demand for diagnostic imaging is fueling the technetium-99m market’s growth.
Companies in the technetium-99m market are focusing on developing innovative solutions such as advanced radiopharmaceutical imaging agents to improve the accuracy and accessibility of diagnostic imaging for complex medical conditions. These agents are special compounds labeled with radioactive materials that help doctors visualize internal body structures using imaging techniques. For instance, in June 2024, Serac Healthcare Limited, a UK-based clinical radiopharmaceutical company, received Fast Track Designation from the US FDA for 99mTc-maraciclatide, an innovative SPECT-CT imaging agent designed to visualize and diagnose superficial peritoneal endometriosis in women aged 16 and older. This agent is a technetium-99m-labeled targeted peptide that binds to integrins overexpressed in endometriosis lesions, allowing clear visualization of disease sites during SPECT-CT scans. It offers a non-invasive diagnostic alternative to laparoscopic procedures, providing a safer and more accessible diagnostic option for women suspected of having endometriosis. Utilizing the favorable imaging characteristics of technetium-99m, including its ideal half-life and gamma emission energy, this agent delivers high-quality diagnostic images while minimizing radiation exposure. This innovation is expected to improve diagnostic accuracy and support better treatment decisions in endometriosis management, while broadening the clinical use of technetium-99m-based imaging in women’s health.
In April 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired ARTMS Inc. for an undisclosed sum. Through this acquisition, Telix aims to strengthen its control over the supply chain for key medical isotopes such as technetium-99m by integrating ARTMS’s cyclotron-based radioisotope production technology. This move is intended to support large-scale, cost-effective, and reliable production of diagnostic and therapeutic isotopes within Telix’s radiopharmaceutical portfolio. ARTMS Inc. is a Canada-based company specializing in advanced cyclotron technologies for producing medical radioisotopes including technetium-99m.
Major companies operating in the technetium-99m market are Cardinal Health Inc, GE Healthcare Technologies Inc, BWX Technologies Inc, Bracco Imaging S p A, Lantheus Holdings Inc, China Isotope And Radiation Corporation, Jubilant Pharma Limited, Curium Pharma LLC, Eckert And Ziegler Strahlen, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, SHINE Technologies LLC, Medi Radiopharma Kft, SDS Lifesciences Pvt Ltd, ANSTO Nuclear Medicine, IRE ELiT, Sam Young Unitech Co Ltd, RadioMedix Inc, Institute Of Isotopes Co Ltd, Monrol Nuclear Products.
North America was the largest region in the technetium-99m market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the technetium-99m market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the technetium-99m market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the technetium-99m market by increasing the cost of imported radiopharmaceuticals, generators, and diagnostic kits, thereby impacting overall pricing and supply chain efficiency. The hospital-based generators and centralized radiopharmacy segments, particularly in regions like North America and Europe that rely on imports, are most affected. While tariffs may cause short-term cost increases, they also encourage local production of generators and radiopharmaceuticals, potentially leading to innovation and self-reliance in the nuclear medicine supply chain.
The technetium-99m market research report is one of a series of new reports that provides technetium-99m market statistics, including technetium-99m industry global market size, regional shares, competitors with a technetium-99m market share, detailed technetium-99m market segments, market trends and opportunities, and any further data you may need to thrive in the technetium-99m industry. This technetium-99m market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Technetium-99m (Tc-99m) is a radioactive isotope of technetium commonly used in nuclear medicine for diagnostic imaging. It emits gamma rays that can be detected by a gamma camera, enabling visualization of internal organs and structures. With a short half-life of approximately 6 hours, Tc-99m limits patient radiation exposure while delivering clear imaging results.
The primary products related to technetium-99m include radiopharmaceuticals, diagnostic kits, and generators. Radiopharmaceuticals are radioactive compounds used in medical imaging and therapy for diagnosis or treatment. These are available in various formulations such as liquid, solid, and freeze-dried forms. Applications span single photon emission computed tomography (SPECT), positron emission tomography (PET), oncology, cardiology, neurology, and more. The key end users include hospitals, diagnostic imaging centers, research laboratories, specialized clinics, and other healthcare facilities.
The technetium-99m market includes revenues earned by entities by providing services such as diagnostic imaging, functional imaging, medical diagnostic imaging, cardiac imaging, and cancer detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The technetium-99m market also includes sales of technetium-99m sestamibi, mercaptoacetyltriglycine, hexamethylpropyleneamine oxime, technetium-99m pertechnetate, and diethylenetriamine pentaacetic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Technetium-99m Market Characteristics
3. Technetium-99m Market Supply Chain Analysis
4. Global Technetium-99m Market Trends and Strategies
5. Technetium-99m Market Analysis of End Use Industries
7. Global Technetium-99m Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Technetium-99m Total Addressable Market (TAM) Analysis for the Market
9. Technetium-99m Market Segmentation
10. Technetium-99m Market Regional and Country Analysis
11. Asia-Pacific Technetium-99m Market
12. China Technetium-99m Market
13. India Technetium-99m Market
14. Japan Technetium-99m Market
15. Australia Technetium-99m Market
16. Indonesia Technetium-99m Market
17. South Korea Technetium-99m Market
18. Taiwan Technetium-99m Market
19. South East Asia Technetium-99m Market
20. Western Europe Technetium-99m Market
21. UK Technetium-99m Market
22. Germany Technetium-99m Market
23. France Technetium-99m Market
24. Italy Technetium-99m Market
25. Spain Technetium-99m Market
26. Eastern Europe Technetium-99m Market
27. Russia Technetium-99m Market
28. North America Technetium-99m Market
29. USA Technetium-99m Market
30. Canada Technetium-99m Market
31. South America Technetium-99m Market
32. Brazil Technetium-99m Market
33. Middle East Technetium-99m Market
34. Africa Technetium-99m Market
36. Technetium-99m Market Competitive Landscape and Company Profiles
37. Technetium-99m Market Other Major and Innovative Companies
40. Technetium-99m Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Technetium-99m Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses technetium-99m market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for technetium-99m? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The technetium-99m market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Radiopharmaceuticals; Diagnostic Kits; Generators2) By Formulation Type: Liquid; Solid; Freeze-Dried
3) By Application: Single Photon Emission Computed Tomography (SPECT) Imaging; Oncology; Cardiology; Neurology; Other Applications
4) By End-User: Hospitals; Diagnostic Imaging Centers; Research Laboratories; Specialized Clinics; Other End-Users
Subsegments:
1) By Radiopharmaceuticals: Sestamibi; Tetrofosmin; Sulfur Colloid; MAA (Macroaggregated Albumin); DTPA (Diethylenetriaminepentaacetic Acid)2) By Diagnostic Kits: Cardiac Imaging Kits; Bone Imaging Kits; Renal Imaging Kits; Hepatobiliary Imaging Kits; Pulmonary Imaging Kits
3) By Generators: Hospital-Based Generators; Centralized Radiopharmacy Generators
Companies Mentioned: Cardinal Health Inc; GE Healthcare Technologies Inc; BWX Technologies Inc; Bracco Imaging S p A; Lantheus Holdings Inc; China Isotope And Radiation Corporation; Jubilant Pharma Limited; Curium Pharma LLC; Eckert And Ziegler Strahlen; NorthStar Medical Radioisotopes LLC; NTP Radioisotopes SOC Ltd; Isotopia Molecular Imaging Ltd; Cyclopharm Limited; SHINE Technologies LLC; Medi Radiopharma Kft; SDS Lifesciences Pvt Ltd; ANSTO Nuclear Medicine; IRE ELiT; Sam Young Unitech Co Ltd; RadioMedix Inc; Institute Of Isotopes Co Ltd; Monrol Nuclear Products
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Technetium-99m market report include:- Cardinal Health Inc
- GE Healthcare Technologies Inc
- BWX Technologies Inc
- Bracco Imaging S p A
- Lantheus Holdings Inc
- China Isotope And Radiation Corporation
- Jubilant Pharma Limited
- Curium Pharma LLC
- Eckert And Ziegler Strahlen
- NorthStar Medical Radioisotopes LLC
- NTP Radioisotopes SOC Ltd
- Isotopia Molecular Imaging Ltd
- Cyclopharm Limited
- SHINE Technologies LLC
- Medi Radiopharma Kft
- SDS Lifesciences Pvt Ltd
- ANSTO Nuclear Medicine
- IRE ELiT
- Sam Young Unitech Co Ltd
- RadioMedix Inc
- Institute Of Isotopes Co Ltd
- Monrol Nuclear Products
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.99 Billion |
| Forecasted Market Value ( USD | $ 6.01 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
